+1 (786) 916 6163 info@akcellbio.com

Order number AK1606-S 100 assays

The AKCELL EGFR AK™PCR Mutation Screen Kit is designed to screen for mutations on the Epidermal growth factor receptor (EGFR) gene in genomic DNA, commonly associated with lung adenocarcinomas.

EGFR Mutations and Cancer

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.[1] The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.[2]

Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers[3] and glioblastoma multiforme. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division.[4] In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed.[5] Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers.

Compatible with ABI 7500 Real-Time Systems or equivalent.

Intended Use
AKCELL’s EGFR mutation screen reagents are provided for research use only (RUO).

1- Herbst RS (2004). “Review of epidermal growth factor receptor biology”. Int. J. Radiat. Oncol. Biol. Phys. 59 (2 Suppl): 21–6.

2- Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (August 2007).

3- Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, Lehy T, Aparicio T (November 2009). “Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus”. Hum. Pathol. 40 (11): 1517–27.

4- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (May 2004). “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib”. N. Engl. J. Med. 350 (21): 2129–39.

5- Kuan CT, Wikstrand CJ, Bigner DD (June 2001). “EGF mutant receptor vIII as a molecular target in cancer therapy”. Endocr. Relat. Cancer 8 (2): 83–96.